Article
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Genome biology - 26 Jan 2016
Lallous Nada, Volik Stanislav V, Awrey Shannon, Leblanc Eric, Tse Ronnie, Murillo Josef, Singh Kriti, Azad Arun A, Wyatt Alexander W, LeBihan Stephane, Chi Kim N, Gleave Martin E, Rennie Paul S, Collins Colin C, Cherkasov Artem
Abstract excerpt
BACKGROUND: The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen binding site of the receptor, competing with endogenous androgenic steroids. Several AR mutations in this binding site have been associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.